Effects of gastric secretion inhibitors on pharmacokinetics and pharmacodynamics of EGFR-tyrosine kinase inhibitor, gefitinib in patients with non-small cell lung carcinoma

• In: Posters
• At: Dublin (Ireland) (2013)
• Type: Poster
• By: NISHIMURA, Nobuhiro (Shimane University Hospital, Pharmacy, Izumo, Japan)
• Co-author(s): Kojima, Sumire (Shimane University Hospital, Izumo, Japan)
  Okazaki, Mika (Shimane University Hospital, Izumo, Japan)
  Inoue, Masaki (Shimane University Hospital, Izumo, Japan)
  Suyama, Takayuki (Shimane University Hospital, Izumo, Japan)
  Tamaki, Hiroki (Shimane University Hospital, Izumo, Japan)
  Tsubata, Yukari (Shimane University Faculty of Medicine, Izumo, Japan)
  Sutani, Akihisa (Shimane University Faculty of Medicine, Izumo, Japan)
  Isobe, Takeshi (Shimane University Faculty of Medicine, Izumo, Japan)
  Naora, Kohji (Shimane University Hospital, Izumo, Japan)
  
• Abstract:

  Background:
  
  Gefitinib is highly effective at inhibiting the EGFR-tyrosine kinase of non-small cell lung cancer (NSCLC), whereas skin rash is frequently observed as the toxicity leading to reduced QOL in patients.
  
  Aims:
  
  In this study, we investigated the effects of the proton pump inhibitors (PPIs), a gastric acid suppressant, on the clinical..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login